The National Institutes of Health Renews License With Bioalma in Multi-Year Deal

The National Institutes of Health Renews License With Bioalma in Multi-Year Deal

Primary U.S. Federal Agency for Conducting and Supporting Medical Research to Use Text Mining Technology for Human Salivary Proteome Project

MADRID, SPAIN--(Marketwire - May 18, 2009) - Bioalma today announced that the National Institutes of Health (NIH) has licensed AlmaKnowledgeServer 2 (AKS2) software, the company's informatics system which contains powerful tools to search, analyze, and visualize all types of information extracted from biomedical literature. AKS2 is a subscription-based system, and is the technology that is the basis for Bioalma's free biomedical search tool -- novo|seek.

The Center for Information Technology (CIT) at the NIH has expanded its licenses of AKS2 by more than 25 percent to ensure that researchers involved in the human salivary proteome project can utilize the solution as the annotation platform for the project -- a project with a long-term goal of supporting the discovery of saliva-based diagnostic tests. Saliva-based tests hope to provide new "non-invasive" diagnostic methods that can be performed for little cost in a doctor's office or at a patient's home.

"Being selected yet again by the NIH -- the go-to resource for biomedical research in the US -- is a proof point to the powerful capabilities behind our text mining technology -- within both AKS2 and novo|seek," said Ramon Alonso-Allende, director of marketing and business development, Bioalma. "Our overarching goal is to put the power of information into the hands of researchers, medical students, doctors, and librarians, and we continue to add functionality and expanded resources to our family of biomedical search tools to solve that ever-increasing problem of mining overwhelming amounts of scientific literature."

Bioalma will be exhibiting novo|seek -- a powerful alternative to traditional information retrieval systems aimed at a variety of audiences within the biomedical community -- at the Bio International Convention this week at booth #1405/M06.

Tags/keywords: biomedical research, National Institutes of Health, NIH, research, novo|seek, AKS2

Supporting Resources:

To download the Bioalma corporate backgrounder, please visit:

For information on AKS2:

For more information on novo|seek, visit:


Twitter feed:

Facebook group:

LinkedIn group:

About novo|seek

Novo|seek is a dynamic information extraction system for searching the published knowledge in biomedical literature.

Novo|seek indexes the biomedical literature with text mining technology built by Bioalma that identifies key biomedical terms taking into account external available data and contextual term information. As a result of this indexing technology, novo|seek retrieves every document where a term is mentioned no matter the synonym used and discards those documents where the term is used with an unwanted meaning.

About Bioalma

Located in Madrid, Spain, Bioalma is an IT company specialized in the research and development of biomedical software.

Bioalma was founded in 2000 as a spin-off of a bioinformatics group in the National Center of Biotechnology and a privately-held company, as part of the Bionostra group. Bioalma prides itself on an elite team of well-known, internationally-leading scientists as part of its scientific committee and has successfully marketed its technology to different research institutions, universities, pharmaceutical and biotech companies, including National Institutes of Health, Universidad Nacional Autonoma de Mexico, Roche and Althea Technologies.

Bioalma is a privately-owned company, part of the Bionostra group. The Bionostra Group is composed of four companies that share the common objective of being leaders in the biotechnology and bioinformatics sectors. Its main activity is scientific research focused on the development of new technologies, products and biotechnology services within the field of human health. Bionostra Group is composed of Bioalma, ChimeraPharma, Bionostra and Microbionta.

Suggested Articles

No biohazardous substances were in the room where the explosion happened, according to the Russian virology center.

Merck has a shot at becoming the first company to receive clearance to sell a vaccine against the virus in the U.S.

Acceleron has chalked up another phase 2 flop as its pipeline thins a little more.